This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Abhimanyu Garg, MBBS, MD; Scott M. Grundy, MD, PhD

JAMA. 1990;264(6):723-726.

Abstract
Recently, nicotinic acid has been recommended as a first-line hypolipidemic drug. To determine the effectiveness of nicotinic acid in dyslipidemic patients with non—insulin-dependent diabetes mellitus, 13 patients were treated in a randomized crossover trial. Patients received either nicotinic acid (1.5 g three times daily) or no therapy (control period) for 8 weeks each. Compared with the control period, nicotinic acid therapy reduced the plasma total cholesterol level by 24%, plasma triglyceride level by 45%, very-low-density lipoprotein cholesterol level by 58%, and low-density lipoprotein cholesterol level by 15% and it increased the high-density lipoprotein cholesterol level by 34%. However, nicotinic acid therapy resulted in the deterioration of glycemic control, as evidenced by a 16% increase in mean plasma glucose concentrations, a 21% increase in glycosylated hemoglobin levels, and the induction of marked glycosuria in some patients. Furthermore, a consistent increase in plasma uric acid levels was observed. Therefore, despite improvement in lipid and lipoprotein concentrations, because of worsening hyperglycemia and the development of hyperuricemia, nicotinic acid must be used with caution in patients with non—insulin-dependent diabetes mellitus with dyslipidemia. We suggest that the drug not be used as a first-line hypolipidemic drug in patients with non—insulin-dependent diabetes mellitus.

(JAMA. 1990;264:723-726)

Author Affiliations
From the Veterans Administration Medical Center, Dallas (Drs Garg and Grundy), and the Center for Human Nutrition (Drs Garg and Grundy) and the Departments of Clinical Nutrition (Drs Garg and Grundy), Internal Medicine (Drs Garg and Grundy), and Biochemistry (Dr Grundy), University of Texas Southwestern Medical Center at Dallas.

Footnotes
Reprint requests to Center for Human Nutrition, 5323 Harry Hines Blvd, Dallas,TX 75235-9052(DrGrundy).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Lactate Inhibits Lipolysis in Fat Cells through Activation of an Orphan G-protein-coupled Receptor, GPR81
Liu et al.
J. Biol. Chem. 2009;284:2811-2822.
ABSTRACT | FULL TEXT  

Effects of Niacin on Glucose Control in Patients With Dyslipidemia
Goldberg and Jacobson
Mayo Clin Proc. 2008;83:470-478.
ABSTRACT | FULL TEXT  

The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease
Windler et al.
Diabetes and Vascular Disease Research 2007;4:136-142.
ABSTRACT  

Dyslipidemia in a Patient With Type 2 Diabetes
Anderson
Clin. Diabetes 2006;24:189-190.
FULL TEXT  

Diabetic dyslipidaemia: the triad
Wierzbicki
Eur Heart J Suppl 2006;8:F30-F33.
ABSTRACT | FULL TEXT  

REVIEW: Efficacy and Mechanisms of Action of Statins in the Treatment of Diabetic Dyslipidemia
Ginsberg
J. Clin. Endocrinol. Metab. 2006;91:383-392.
ABSTRACT | FULL TEXT  

Reducing cardiovascular risk in patients with type 2 diabetes: the potential contribution of nicotinic acid
Van Gaal et al.
British Journal of Diabetes & Vascular Disease 2005;5:344-350.
ABSTRACT  

Role of nicotinic acid in raising high-density lipoprotein cholesterol (HDL-C) to reduce cardiovascular risk: an Asian/Pacific consensus: The Pan-Asian Consensus Panel On Hdl-C
Barter
British Journal of Diabetes & Vascular Disease 2005;5:S1-S15.
ABSTRACT  

Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: A meta-analysis of randomized controlled trials
Birjmohun et al.
J Am Coll Cardiol 2005;45:185-197.
ABSTRACT | FULL TEXT  

Atherosclerosis Imaging and the Future of Lipid Management
Grundy
Circulation 2004;110:3509-3511.
FULL TEXT  

A Practical and Evidence-Based Approach to Cardiovascular Disease Risk Reduction
Gluckman et al.
Arch Intern Med 2004;164:1490-1500.
ABSTRACT | FULL TEXT  

New Perspectives on the Use of Niacin in the Treatment of Lipid Disorders
McKenney
Arch Intern Med 2004;164:697-705.
ABSTRACT | FULL TEXT  

Review: Use of nicotinic acid in patients with elevated fasting glucose, diabetes, or metabolic syndrome
Mcgovern
British Journal of Diabetes & Vascular Disease 2004;4:78-85.
ABSTRACT  

References
Circulation 2002;106:3373-3421.
FULL TEXT  

Efficacy, Safety, and Tolerability of Once-Daily Niacin for the Treatment of Dyslipidemia Associated With Type 2 Diabetes: Results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial
Grundy et al.
Arch Intern Med 2002;162:1568-1576.
ABSTRACT | FULL TEXT  

New Strategies for the Treatment of Diabetic Dyslipidemia
Haffner and Goldberg
Diabetes Care 2002;25:1237-1239.
FULL TEXT  

Use of Nicotinic Acid in the Management of Recurrent Hypoglycemic Episodes in Diabetes
Hannan and Davoren
Diabetes Care 2001;24:1301-1301.
FULL TEXT  

Effect of Niacin on Lipid and Lipoprotein Levels and Glycemic Control in Patients With Diabetes and Peripheral Arterial Disease: The ADMIT Study: A Randomized Trial
Elam et al.
JAMA 2000;284:1263-1270.
ABSTRACT | FULL TEXT  

Effects of nicotinic acid on fatty acid kinetics, fuel selection, and pathways of glucose production in women
Wang et al.
Am. J. Physiol. Endocrinol. Metab. 2000;279:E50-E59.
ABSTRACT | FULL TEXT  

Pathophysiology of Type 2 Diabetes and Modes of Action of Therapeutic Interventions
Dagogo-Jack and Santiago
Arch Intern Med 1997;157:1802-1817.
ABSTRACT  

Nicotinic Acid as a Lipoprotein-Altering Agent: Therapy Directed by the Primary Physician
Probstfield and Hunninghake
Arch Intern Med 1994;154:1557-1559.
ABSTRACT  

Lipoprotein Responses to Treatment With Lovastatin, Gemfibrozil, and Nicotinic Acid in Normolipidemic Patients With Hypoalphalipoproteinemia
Vega and Grundy
Arch Intern Med 1994;154:73-82.
ABSTRACT  

Severe Reversible Hyperglycemia as a Consequence of Niacin Therapy
Schwartz
Arch Intern Med 1993;153:2050-2052.
ABSTRACT  

Vitamin and Mineral Supplementation in Patients with Diabetes Mellitus
Baker and Campbell
The Diabetes Educator 1992;18:420-427.
 

Two Different Views of the Relationship of Hypertriglyceridemia to Coronary Heart Disease: Implications for Treatment
Grundy and Vega
Arch Intern Med 1992;152:28-34.
ABSTRACT  

NICOTINIC ACID WORSENS GLUCOSE CONTROL IN DIABETICS
JWatch General 1990;1990:1-1.
FULL TEXT